Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04186871 · ClinicalTrials.gov registry record · Phase 2

Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis

A Phase 2 study of Rheumatoid Arthritis and Systemic Lupus Erythematosus, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 2
Development phase
119
Enrollment target
20
Study locations

NCT04186871 is a Phase 2 study of Rheumatoid Arthritis and Systemic Lupus Erythematosus that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 119 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04186871, a Phase 2 study of Rheumatoid Arthritis and Systemic Lupus Erythematosus, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 2
Development phase
119 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety and effectiveness of treatment with branebrutinib treatment in participants with active systemic Lupus Erythematosus (SLE) or Primary Sjögren's Syndrome (pSS), or branebrutinib treatment followed by open-label abatacept treatment in study participants with active Rheumatoid Arthritis (RA).

Conditions Studied

Rheumatoid Arthritis Systemic Lupus Erythematosus Primary Sjögren's Syndrome Autoimmune Disorder

Interventions

  • DRUG abatacept
  • DRUG branebrutinib
  • DRUG branebrutinib placebo

Study Locations (20)

Florida

  • Local Institution - Brandon
  • Local Institution - 0062 - DeBary
  • Local Institution - 0035 - Hialeah
  • Local Institution - Jacksonville
  • Local Institution - 0029 - Plantation

California

  • Local Institution - 0002 - Covina
  • Local Institution - 0024 - Encino
  • Local Institution - 0034 - San Diego
  • Local Institution - 0032 - Upland

Michigan

  • Local Institution - 0041 - Ann Arbor
  • Local Institution - 0082 - Grand Blanc

Missouri

  • Local Institution - 0096 - St Louis
  • Local Institution - 0040 - St Louis

Arizona

  • Local Institution - 0019 - Phoenix

Georgia

  • Local Institution - 0009 - Lawrenceville

Illinois

  • Local Institution - 0014 - Skokie

Indiana

  • Local Institution - Evansville

Trial Details

FieldValue
Enrollment Target 119 participants
Start Date 2020-01-07
Est. Completion 2022-12-05
Phase Phase 2

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04186871

The ClinicalTrials.gov registry entry for NCT04186871 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (97% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 3 interventions - of which abatacept is the first listed.

NCT04186871 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Michigan.

Frequently Asked Questions

What is clinical trial NCT04186871 about?

NCT04186871 is a clinical study titled "Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis". The purpose of this study is to evaluate the safety and effectiveness of treatment with branebrutinib treatment in participants with active systemic Lupus Erythematosus (SLE) or Primary Sjögren's Syndrome (pSS), or branebrutinib treatment followed by open-label abatacept treatment in study participa...

What is the current status of trial NCT04186871?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 119 participants. The study started on 2020-01-07. Estimated completion is 2022-12-05.

What conditions does trial NCT04186871 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis, Systemic Lupus Erythematosus, Primary Sjögren's Syndrome, Autoimmune Disorder.

What interventions are being tested in trial NCT04186871?

The interventions under investigation include: abatacept (DRUG), branebrutinib (DRUG), branebrutinib placebo (DRUG).

Who is sponsoring clinical trial NCT04186871?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04186871 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Rheumatoid Arthritis

All registered trials for this condition

Systemic Lupus Erythematosus

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.